Loading...

We've got a brand new version of Simply Wall St! Try it out

Youngevity International

Nasdaq:YGYI.P
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
YGYI.P
Nasdaq
$115M
Market Cap
  1. Home
  2. US
  3. Household
Company description

Youngevity International, Inc. develops and distributes health and nutrition related products and services in the United States and internationally. The last earnings update was 91 days ago. More info.


Add to Portfolio Compare Print
YGYI.P Share Price and Events
7 Day Returns
-0%
NasdaqCM:YGYI.P
2.2%
US Personal Products
0.3%
US Market
1 Year Returns
-
NasdaqCM:YGYI.P
20.5%
US Personal Products
12.5%
US Market
YGYI.P Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Youngevity International (YGYI.P) -0% 1.6% - - - -
US Personal Products 2.2% -1.1% 5.5% 20.5% 54.3% 59.2%
US Market 0.3% 4.1% 5.6% 12.5% 39.4% 44.7%
1 Year Return vs Industry and Market
  • No trading data on YGYI.P.
  • No trading data on YGYI.P.
Price Volatility
YGYI.P
Industry
5yr Volatility vs Market

YGYI.P Value

 Is Youngevity International undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Youngevity International. This is due to cash flow or dividend data being unavailable. The share price is $24.7.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Youngevity International's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Youngevity International's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:YGYI.P PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in USD $-1.29
NasdaqCM:YGYI Share Price ** NasdaqCM (2019-11-12) in USD $3.81
United States of America Personal Products Industry PE Ratio Median Figure of 21 Publicly-Listed Personal Products Companies 17.08x
United States of America Market PE Ratio Median Figure of 2,922 Publicly-Listed Companies 18.25x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Youngevity International.

NasdaqCM:YGYI.P PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:YGYI Share Price ÷ EPS (both in USD)

= 3.81 ÷ -1.29

-2.95x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Youngevity International is loss making, we can't compare its value to the US Personal Products industry average.
  • Youngevity International is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Youngevity International's expected growth come at a high price?
Raw Data
NasdaqCM:YGYI.P PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.95x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
146.6%per year
United States of America Personal Products Industry PEG Ratio Median Figure of 6 Publicly-Listed Personal Products Companies 2.56x
United States of America Market PEG Ratio Median Figure of 2,023 Publicly-Listed Companies 1.46x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Youngevity International, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Youngevity International's assets?
Raw Data
NasdaqCM:YGYI.P PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in USD $1.72
NasdaqCM:YGYI Share Price * NasdaqCM (2019-11-12) in USD $3.81
United States of America Personal Products Industry PB Ratio Median Figure of 43 Publicly-Listed Personal Products Companies 2.65x
United States of America Market PB Ratio Median Figure of 5,066 Publicly-Listed Companies 1.74x
NasdaqCM:YGYI.P PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:YGYI Share Price ÷ Book Value per Share (both in USD)

= 3.81 ÷ 1.72

2.21x

* Primary Listing of Youngevity International.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Youngevity International is good value based on assets compared to the US Personal Products industry average.
X
Value checks
We assess Youngevity International's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Personal Products industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Personal Products industry average (and greater than 0)? (1 check)
  5. Youngevity International has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

YGYI.P Future Performance

 How is Youngevity International expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
146.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Youngevity International expected to grow at an attractive rate?
  • Youngevity International's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Youngevity International's earnings growth is expected to exceed the United States of America market average.
  • Youngevity International's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:YGYI.P Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:YGYI.P Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 146.6%
NasdaqCM:YGYI.P Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 29.5%
United States of America Personal Products Industry Earnings Growth Rate Market Cap Weighted Average 17.7%
United States of America Personal Products Industry Revenue Growth Rate Market Cap Weighted Average 6.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.2%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:YGYI.P Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:YGYI.P Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 280 9 1
2019-12-31 200 -13 1
2019-11-13
NasdaqCM:YGYI.P Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-06-30 185 -16 -33
2019-03-31 176 -16 -33
2018-12-31 162 -12 -23
2018-09-30 167 -6 -20
2018-06-30 173 -4 -11
2018-03-31 170 -4 -13
2017-12-31 166 -3 -13
2017-09-30 163 -3 -6
2017-06-30 162 -1 -5
2017-03-31 163 -3 -3
2016-12-31 163 -2 0
2016-09-30 164 1 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Youngevity International's earnings are expected to grow significantly at over 20% yearly.
  • Youngevity International's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:YGYI.P Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Youngevity International Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:YGYI.P Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 0.29 0.29 0.29 1.00
2019-12-31 -0.47 -0.47 -0.47 1.00
2019-11-13
NasdaqCM:YGYI.P Past Financials Data
Date (Data in USD Millions) EPS *
2019-06-30 -1.29
2019-03-31 -1.42
2018-12-31 -1.09
2018-09-30 -0.95
2018-06-30 -0.54
2018-03-31 -0.66
2017-12-31 -0.65
2017-09-30 -0.32
2017-06-30 -0.27
2017-03-31 -0.13
2016-12-31 -0.02
2016-09-30 -0.06

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Youngevity International will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Youngevity International's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Youngevity International has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

YGYI.P Past Performance

  How has Youngevity International performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Youngevity International's growth in the last year to its industry (Personal Products).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Youngevity International does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Youngevity International's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Youngevity International's 1-year growth to the US Personal Products industry average as it is not currently profitable.
Earnings and Revenue History
Youngevity International's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Youngevity International Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:YGYI.P Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 185.18 -32.88 114.68
2019-03-31 175.75 -33.46 114.68
2018-12-31 162.45 -23.50 101.09
2018-09-30 167.37 -19.68 102.18
2018-06-30 172.69 -10.86 104.56
2018-03-31 169.96 -12.94 104.05
2017-12-31 165.70 -12.69 103.11
2017-09-30 163.06 -6.38 101.65
2017-06-30 162.23 -5.24 99.83
2017-03-31 163.20 -2.62 98.76
2016-12-31 162.67 -0.41 97.08
2016-09-30 163.99 -1.25 95.81
2016-06-30 161.75 -0.90 93.56
2016-03-31 157.99 -1.20 90.69
2015-12-31 156.60 -1.72 88.01
2015-09-30 154.18 3.84 85.74
2015-06-30 150.47 3.61 81.63
2015-03-31 144.45 4.56 77.81
2014-12-31 134.04 5.35 72.78
2014-09-30 119.44 1.66 64.68
2014-06-30 103.03 1.99 56.89
2014-03-31 91.20 2.12 50.81
2013-12-31 85.63 2.75 46.90
2013-09-30 82.15 2.39 44.95
2013-06-30 81.54 2.18 44.95
2013-03-31 79.89 1.47 44.36
2012-12-31 75.00 -0.44 42.98

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Youngevity International has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Youngevity International has efficiently used its assets last year compared to the US Personal Products industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Youngevity International improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Youngevity International's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Personal Products industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Youngevity International has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

YGYI.P Health

 How is Youngevity International's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Youngevity International's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Youngevity International is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Youngevity International's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Youngevity International's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 4.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Youngevity International Company Filings, last reported 4 months ago.

NasdaqCM:YGYI.P Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 50.54 15.76 2.09
2019-03-31 47.62 15.63 2.54
2018-12-31 22.98 11.18 2.88
2018-09-30 11.73 15.08 2.30
2018-06-30 15.83 13.91 0.70
2018-03-31 15.44 15.30 3.05
2017-12-31 7.45 19.52 0.67
2017-09-30 14.62 18.41 1.37
2017-06-30 14.87 16.64 0.90
2017-03-31 17.01 16.11 1.02
2016-12-31 19.00 14.27 0.87
2016-09-30 19.13 14.22 2.01
2016-06-30 18.92 12.30 1.83
2016-03-31 18.99 12.22 2.73
2015-12-31 18.88 12.35 3.88
2015-09-30 19.26 11.59 1.98
2015-06-30 18.32 11.74 2.63
2015-03-31 18.84 11.71 4.27
2014-12-31 18.59 5.46 3.00
2014-09-30 14.01 5.28 5.38
2014-06-30 12.85 5.72 4.14
2014-03-31 12.03 5.73 6.75
2013-12-31 11.50 5.26 4.32
2013-09-30 10.78 5.33 4.39
2013-06-30 10.08 5.41 3.64
2013-03-31 9.38 5.49 4.12
2012-12-31 9.88 1.56 3.03
  • Youngevity International's level of debt (31.2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (44.4% vs 31.2% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Youngevity International has less than a year of cash runway based on current free cash flow.
  • Youngevity International has less than a year of cash runway if free cash flow continues to grow at historical rates of 89.4% each year.
X
Financial health checks
We assess Youngevity International's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Youngevity International has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

YGYI.P Dividends

 What is Youngevity International's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Youngevity International dividends.
If you bought $2,000 of Youngevity International shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Youngevity International's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Youngevity International's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:YGYI.P Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
United States of America Personal Products Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 1.5%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1948 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:YGYI.P Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2019-12-31
2019-11-13

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Youngevity International has not reported any payouts.
  • Unable to verify if Youngevity International's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Youngevity International's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Youngevity International has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Youngevity International's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Youngevity International afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Youngevity International has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

YGYI.P Management

 What is the CEO of Youngevity International's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Steve Wallach
COMPENSATION $434,439
AGE 52
TENURE AS CEO 8.3 years
CEO Bio

Mr. Stephan Wallach, also known as Steve, has been the Chief Executive Officer of Youngevity International Inc. (formerly, AL International Inc.) since July 11, 2011 and served as its President. Mr. Wallachs serves as the Chief Executive Officer of Drink Act.com and Youngevity Essential Life Sciences. He served as the President and Chief Executive Officer of Javalution Coffee Company. Mr. Wallachs has over 15 years of sales and network marketing experience. He served as President and Chief Executive Officer of AL Global Corporation d/b/a Youngevity® Essential Life Sciences. He has been the Chairman and Director of Youngevity International, Inc. since January 9, 2012 and 2011 respectively.

CEO Compensation
  • Steve's compensation has increased whilst company is loss making.
  • Steve's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Youngevity International management team in years:

8.3
Average Tenure
58
Average Age
  • The average tenure for the Youngevity International management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Steve Wallach

TITLE
Chairman & CEO
COMPENSATION
$434K
AGE
52
TENURE
8.3 yrs

Dave Briskie

TITLE
President
COMPENSATION
$1M
AGE
58
TENURE
4.1 yrs

Michelle Wallach

TITLE
COO & Director
COMPENSATION
$215K
AGE
48
TENURE
8.3 yrs

Joel Wallach

TITLE
Co-Founder
TENURE
22.8 yrs

Ma Lan

TITLE
Co-Founder & Member of the Scientific Advisory Board
TENURE
22.8 yrs

Brad Kenson

TITLE
Chief Technology Officer
AGE
60
TENURE
4 yrs

Jonnie Taylor

TITLE
Senior Executive Vice President of Customer Service

Raffy Lorentzian

TITLE
VP & Controller
AGE
63
TENURE
6.4 yrs

Dwayne Dundore

TITLE
President of Khrysos

Wiley Hurt

TITLE
VP of Global Operations & Senior Project Manager
Board of Directors Tenure

Average tenure and age of the Youngevity International board of directors in years:

7.8
Average Tenure
58
Average Age
  • The tenure for the Youngevity International board of directors is about average.
Board of Directors

Steve Wallach

TITLE
Chairman & CEO
COMPENSATION
$434K
AGE
52
TENURE
7.8 yrs

Dave Briskie

TITLE
President
COMPENSATION
$1M
AGE
58
TENURE
8.8 yrs

Michelle Wallach

TITLE
COO & Director
COMPENSATION
$215K
AGE
48
TENURE
8.8 yrs

Joel Wallach

TITLE
Co-Founder

Ma Lan

TITLE
Co-Founder & Member of the Scientific Advisory Board

Mike Glenn

TITLE
Chairman of the Athletic Advisory Board

Bill Thompson

TITLE
Independent Director
COMPENSATION
$74K
AGE
58
TENURE
6.4 yrs

Paul Sallwasser

TITLE
Independent Director
COMPENSATION
$74K
AGE
65
TENURE
2.4 yrs

Gerhard Schrauzer

TITLE
Member of the Scientific Advisory Board

James Sensenig

TITLE
Member of the Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Youngevity International's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Youngevity International has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

YGYI.P News

Simply Wall St News

YGYI.P Company Info

Description

Youngevity International, Inc. develops and distributes health and nutrition related products and services in the United States and internationally. It operates in three segments: Direct Selling, Commercial Coffee, and Commercial Hemp. The company offers nutritional supplements, gourmet coffee, weight management products, skincare and cosmetics, health and wellness, packaged foods, lifestyle products, pet care, digital products, telecare health services, apparel and fashion accessories, and business lending products. It also produces and sells coffee products under the Café La Rica, Café Alma, Josie’s Java House, Javalution Urban Grind, Javalution Daily Grind, and Javalution Royal Roast brands; and produces and markets a line of coffees under the JavaFit brand directly to consumers. In addition, it offers cannabidiol oils from hemp stock. The company sells coffee and equipment to wellness and retirement communities, and various cruise lines and coffee service operators, as well as through distribution network. Youngevity International, Inc. also markets its products through a range of consumer Websites, such as youngevity.com; ygyi.com; heritagemakers.com; hempfx.com; clrroasters.com; cafelarica.com; javalution.com. The company was formerly known as AL International, Inc. and changed its name to Youngevity International, Inc. in July 2013. Youngevity International, Inc. was founded in 1996 and is headquartered in Chula Vista, California.

Details
Name: Youngevity International, Inc.
YGYI.P
Exchange: NasdaqCM
Founded: 1996
$114,608,762
30,081,040
Website: http://www.ygyi.com
Address: Youngevity International, Inc.
2400 Boswell Road,
Chula Vista,
California, 91914,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM YGYI Common Stock Nasdaq Capital Market US USD 12. Jul 2011
BST 2OV Common Stock Boerse-Stuttgart DE EUR 12. Jul 2011
NasdaqCM YGYI.P 9.75% PFD SER D Nasdaq Capital Market US USD 20. Sep 2019
Number of employees
Current staff
Staff numbers
469
Youngevity International employees.
Industry
Personal Products
Household
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/13 00:50
End of day share price update: 2019/11/12 00:00
Last estimates confirmation: 2019/08/20
Last earnings filing: 2019/08/14
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.